Clinical Efficacy and Safety of Immunotherapy Retreatment in Metastatic Cervical Cancer: A Retrospective Study

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Waggoner SE. Cervical cancer. Lancet. 2003;361(9376):2217–2225. doi:10.1016/S0140-6736(03)13778-6
   PubMed Web of Science ®Google Scholar
• Tewari KS, Sill MW, Long HJ, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370(8):734–743. doi:10.1056/NEJMoa1309748
   PubMed Web of Science ®Google Scholar
• Frenel JS, Le Tourneau C, O’Neil B, et al. Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 trial. J Clin Oncol. 2017;35(36):4035–4041. doi:10.1200/JCO.2017.74.5471
   PubMed Web of Science ®Google Scholar
• Chung HC, Ros W, Delord JP, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2019;37(17):1470–1478. doi:10.1200/JCO.18.01265
   PubMed Web of Science ®Google Scholar
• Naumann RW, Hollebecque A, Meyer T, et al. Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I/II CheckMate 358 trial. J Clin Oncol. 2019;37(31):2825–2834. doi:10.1200/JCO.19.00739
   PubMed Web of Science ®Google Scholar
• Lan C, Shen J, Wang Y, et al. Camrelizumab plus Apatinib in patients with advanced cervical cancer (CLAP): a multicenter, open-label, single-arm, Phase II trial. J Clin Oncol. 2020;38(34):4095–4106. doi:10.1200/JCO.20.01920
   PubMed Web of Science ®Google Scholar
• Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Engl J Med. 2021;385(20):1856–1867. doi:10.1056/NEJMoa2112435
   PubMed Web of Science ®Google Scholar
• Wendel Naumann R, Leath CA. Advances in immunotherapy for cervical cancer. Curr Opin Oncol. 2020;32(5):481–487. doi:10.1097/CCO.0000000000000663
   PubMed Web of Science ®Google Scholar
• Fujita K, Uchida N, Kanai O, Okamura M, Nakatani K, Mio T. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases. Cancer Chemother Pharmacol. 2018;81(6):1105–1109. doi:10.1007/s00280-018-3585-9
   PubMed Web of Science ®Google Scholar
• Fujita K, Uchida N, Yamamoto Y, et al. Retreatment with anti-PD-L1 antibody in advanced non-small cell lung cancer previously treated with anti-PD-1 antibodies. Anticancer Res. 2019;39(7):3917–3921. doi:10.21873/anticanres.13543
   PubMed Web of Science ®Google Scholar
• Watanabe H, Kubo T, Ninomiya K, et al. The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer. Jpn J Clin Oncol. 2019;49(8):762–765. doi:10.1093/jjco/hyz066
   PubMed Web of Science ®Google Scholar
• Katayama Y, Shimamoto T, Yamada T, et al. Retrospective efficacy analysis of immune checkpoint inhibitor rechallenge in patients with non-small cell lung cancer. J Clin Med. 2019;9(1):102. doi:10.3390/jcm9010102
   PubMed Web of Science ®Google Scholar
• Abou Alaiwi S, Xie W, Nassar AH, et al. Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma. J Immunother Cancer. 2020;8(1):e000144. doi:10.1136/jitc-2019-000144
   PubMed Web of Science ®Google Scholar
• Yang K, Li J, Sun Z, Zhao L, Bai C. Retreatment with immune checkpoint inhibitors in solid tumors: a systematic review. Ther Adv Med Oncol. 2020;12:1758835920975353. doi:10.1177/1758835920975353
   Web of Science ®Google Scholar
• Markham A, Keam SJ. Camrelizumab: first global approval. Drugs. 2019;79(12):1355–1361. doi:10.1007/s40265-019-01167-0
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.026
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Common terminology criteria for adverse events (CTCAE) common terminology criteria for adverse events (CTCAE) v5,0.; 2017. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm. Accessed March 3, 2023.
   Google Scholar
• Gobbini E, Toffart AC, Pérol M, et al. Immune checkpoint inhibitors rechallenge efficacy in non-small-cell lung cancer patients. Clin Lung Cancer. 2020;21(5):e497–e510. doi:10.1016/j.cllc.2020.04.013
   PubMed Web of Science ®Google Scholar
• Nomura M, Otsuka A, Kondo T, et al. Efficacy and safety of retreatment with nivolumab in metastatic melanoma patients previously treated with nivolumab. Cancer Chemother Pharmacol. 2017;80(5):999–1004. doi:10.1007/s00280-017-3444-0
   PubMed Web of Science ®Google Scholar
• Giaj Levra M, Cotté FE, Corre R, et al. Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: a national data base analysis. Lung Cancer. 2020;140:99–106. doi:10.1016/j.lungcan.2019.12.017
   PubMed Web of Science ®Google Scholar
• Blasig H, Bender C, Hassel JC, et al. Reinduction of PD1-inhibitor therapy: first experience in eight patients with metastatic melanoma. Melanoma Res. 2017;27(4):321–325. doi:10.1097/CMR.0000000000000341
   PubMed Web of Science ®Google Scholar
• Long GV, Schachter J, Arance A, et al. Long-term survival from pembrolizumab (pembro) completion and pembro retreatment: phase III KEYNOTE-006 in advanced melanoma. J Clin Oncol. 2020;38(15_suppl):10013. doi:10.1200/JCO.2020.38.15_suppl.10013
   Web of Science ®Google Scholar
• Herbst RS, Garon EB, Kim DW, et al. Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1‒positive, advanced non‒small-cell lung cancer in the KEYNOTE-010 study. J Clin Oncol. 2020;38(14):1580–1590. doi:10.1200/JCO.19.02446
   PubMed Web of Science ®Google Scholar
• Fernandez AMA, O’Day SJ, Merino LC, et al. LBA44 Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 Inhibitor: initial results of LEAP-004. Ann Oncol. 2020;31:S1173. doi:10.1016/j.annonc.2020.08.2274
   Web of Science ®Google Scholar
• Sandhu SK, Atkinson VG, Cao MG, et al. Interim analysis of a phase Ib study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild type melanoma progressing on prior anti-PD-L1 therapy. Ann Oncol. 2019;30:V554. doi:10.1093/annonc/mdz255.046
   Web of Science ®Google Scholar
• Vera Aguilera JV, Paludo J, McWilliams RR, et al. Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients. Melanoma Res. 2020;30(4):364–375. doi:10.1097/CMR.0000000000000669
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 2015;28(6):690–714. doi:10.1016/j.ccell.2015.10.012
   PubMed Web of Science ®Google Scholar
• Rebuzzi SE, Facchinetti F, Tiseo M. Anti-angiogenesis boosts chemo-immunotherapy in patients with EGFR mutations or baseline liver metastases: insights from IMpower150 study. Transl Cancer Res. 2019;8(Suppl6):S612–S617. doi:10.21037/tcr.2019.06.21
   PubMedGoogle Scholar
• Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15(5):325–340. doi:10.1038/nrclinonc.2018.29
   PubMed Web of Science ®Google Scholar
• Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–2301. doi:10.1056/NEJMoa1716948
   PubMed Web of Science ®Google Scholar